AEMD - Aethlon Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0358
+0.0058 (+0.56%)
As of 1:09PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.0300
Open1.0100
Bid1.0100 x 1000
Ask1.0400 x 1300
Day's Range1.0100 - 1.0452
52 Week Range0.8200 - 1.7400
Volume59,162
Avg. Volume123,613
Market Cap19.639M
Beta (3Y Monthly)-0.42
PE Ratio (TTM)N/A
EPS (TTM)-0.3350
Earnings DateFeb 7, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • PR Newswire12 days ago

    Aethlon Medical, Inc. Announces Appointment of Lisa M. Boswell as Director, Quality Systems and Regulatory Affairs

    SAN DIEGO, March 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic medical device company focused on addressing critical unmet needs in global health, announces the appointment of Lisa M. Boswell, to the position of Director, Quality Systems and Regulatory Affairs.  Ms. Boswell has over 15 years of experience in Quality Control, Quality Assurance and Regulatory Affairs in both the biopharmaceutical and medical device industries, most recently as Director, Quality Assurance and Regulatory Affairs at ZOLL Data Systems, Inc.

  • Zacks Small Cap Researchlast month

    AEMD: Eventual FDA Cancer Indication Is A Realistic Outcome

    Aethlon (AEMD) reported financial results for their fiscal third quarter ending December 31st and provided a business update.  While we had modeled an initial payment under their ongoing NCI grant (The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation), which was awarded in September and will pay a total of $298.4k through ~August 2019, initial revenue is now expected to be recognized in the current (i.e.

  • PR Newswirelast month

    Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

    SAN DIEGO , Feb. 11, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for the third ...

  • ACCESSWIRElast month

    Aethlon Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 11, 2019 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on February 11, 2019 at 4:30 ...

  • PR Newswirelast month

    Aethlon Medical To Release Quarterly Financial Results and Host Conference Call on February 11, 2019

    SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for the third quarter of fiscal year 2019, ended December 31, 2018, at 4:15 pm eastern time on Monday, February 11, 2019. Management will host a conference call on Monday, February 11, 2019 at 4:30 pm eastern time to review financial results and recent corporate developments. International callers should call 1-412-317-5442.

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in Roper Technologies, The AES, D.R. Horton, Forrester Research, Aethlon Medical, and CyberOptics — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Jan. 18, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire3 months ago

    Aethlon Announces Appointment of Timothy Rodell as Interim Chief Executive Officer

    SAN DIEGO, Dec. 13, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today the appointment of Timothy C. Rodell, M.D., FCCP, as Interim Chief Executive Officer, effective as of December 10, 2018.  Dr. Rodell joins Aethlon from GlobeImmune, Inc. where he was President, and Chief Executive Officer and a member of their board of directors prior to the shareholder majority acquisition of the company.  Dr. Rodell brings an impressive record of results in global, strategic and operational roles to Aethlon.  Dr. Rodell succeeds James Joyce, who will serve as a consultant to Aethlon during the transition.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Arsanis and Aethlon Medical

    NEW YORK, NY / ACCESSWIRE / November 28, 2018 / Biotech stocks Arsanis and Aethlon Medical were both seeing big gains on Tuesday on positive developments. Arsanis and privately held X4 Pharmaceuticals have agreed to merge and Aethlon announced it had received Breakthrough Device designation from FDA for their Hemopurifier in the treatment of cancer.

  • Zacks Small Cap Research4 months ago

    AEMD: Breakthrough Device Designation Granted for Cancer Therapy. Could Be Game-Changer for AEMD

    By Brian Marckx, CFA NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Breakthrough Device Designation Granted for Cancer Therapy This morning Aethlon (NASDAQ:AEMD) announced that they received Breakthrough ...

  • ACCESSWIRE4 months ago

    The Reason Healthcare Stocks Are Being Called Home By Investors

    CORAL GABLES, FL / ACCESSWIRE / November 27, 2018 / Healthcare stocks helped boost the stock market rally on Monday. Recently concluded mid-term elections have provided a much-needed boost to the healthcare sector. New trends that the majority of healthcare companies are working on are also boosting the sector.

  • PR Newswire4 months ago

    Aethlon Medical's Cancer Therapy Receives "Breakthrough Device" Designation from the U.S. Food and Drug Administration

    SAN DIEGO, Nov. 27, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that it has received a "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA) to support the advancement of the Aethlon Hemopurifier® for the treatment of cancer.  The Aethlon Hemopurifier is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and life-threatening viruses. FDA's Breakthrough Device program was established under the 21st Century Cures Act to facilitate more rapid patient access to breakthrough technologies with the potential to address life threatening disease conditions for which no approved or cleared treatment alternatives exist.

  • Zacks Small Cap Research4 months ago

    AEMD: Pivot Towards Cancer Makes Sense. FDA Filing For Breakthrough Device in Cancer

    Aethlon (AEMD) reported financial results for their fiscal second quarter ending September 30th and provided an operational update. As we had expected, no revenue was generated in the quarter – we do, however anticipate that revenue will return in fiscal Q3 and reflect initial progress under the recently awarded NCI grant evaluating Hemopurifier in the removal of breast cancer derived exosomes from the blood.

  • GlobeNewswire4 months ago

    Research Report Identifies Prudential Financial, Second Sight Medical Products, Acushnet, Repligen, Scorpio Tankers, and Aethlon Medical with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire4 months ago

    Aethlon Medical Announces Second Quarter Fiscal Year 2019 Results

    SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced results for its fiscal second quarter ...

  • PR Newswire5 months ago

    Aethlon Medical To Release Quarterly Financial Results and Host Conference Call on November 6, 2018

    SAN DIEGO , Nov. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health today announced it will issue financial results for ...

  • PR Newswire5 months ago

    Aethlon Medical to Present at the NYC Oncology Conference

    Aethlon Medical is focused on addressing unmet needs in global health.  The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.

  • PR Newswire5 months ago

    Aethlon Medical to Present at the 2018 BIO Investor Forum

    SAN DIEGO, Oct. 16, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), an immunotherapeutic technology company focused on unmet needs in global health, today announced that its CEO, Jim Joyce, will present at the 2018 BIO Investor Forum on Thursday, October 18, 2018 at 3:15 p.m. Pacific Time.  The event is being held at the Westin St. Francis Hotel in San Francisco, California.  A live audio webcast of the presentation can be accessed at http://www.aethlonmedical.com/news-media/presentations.  A replay of the webcast will be available until January 15, 2019. Aethlon Medical is focused on addressing unmet needs in global health.  The Aethlon Hemopurifier® is clinical-stage immunotherapeutic device candidate to combat cancer and life-threatening viral infections. Aethlon Medical is also the majority owner of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.

  • Simply Wall St.5 months ago

    How Financially Strong Is Aethlon Medical Inc (NASDAQ:AEMD)?

    While small-cap stocks, such as Aethlon Medical Inc (NASDAQ:AEMD) with its market cap of US$20m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...

  • PR Newswire6 months ago

    Aethlon Medical Receives National Cancer Institute Award

    The Aethlon Hemopurifier is a first-in-class therapeutic technology designed for the rapid depletion of circulating viruses and cancer promoting exosomes. The FDA has designated the Hemopurifier as a "Breakthrough Device" for the treatment of life-threatening viruses for which there are no approved therapies.

  • Zacks Small Cap Research7 months ago

    AEMD: Compassionate Use, Real-World Data, Awaiting FDA Final Guidance

    Revenue of $150k represented the final payment from the phase I NCI cancer grant. A subsequent, phase 2 contract worth approximately $1.5M over two years, could follow – AEMD’s application for which is expected to be submitted later this year. Updates to several of the development programs were provided on the call, including that related to Hemopurifier under the Breakthrough Device designation, Hemopurifier’s potential role in cancer therapy and updates in the ESI segment – including CTE/TauSome study enrollment status and potential new opportunities.

  • PR Newswire7 months ago

    Aethlon Medical Announces First Quarter Fiscal Year 2019 Results

    SAN DIEGO , Aug. 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • PR Newswire8 months ago

    Aethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2019 and Host Conference Call on August 8, 2018

    SAN DIEGO , Aug. 2, 2018  /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial ...